Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection - Concepedia

Concepedia

Publication | Open Access

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

DOI Full Paper Access

14

Citations

19

References

2021

Year

Ed Gane, Christian Schwabe, Elina Berliba, Pisit Tangkijvanich, Alina Jucov, Nelea Ghicavii, Thierry Verbinnen, Oliver Lenz, Willem Talloen, Thomas N. Kakuda,

Journal of Antimicrobial Chemotherapy

Abstract

JNJ-64530440 750 mg once-daily or twice-daily for 28 days was well tolerated and achieved potent antiviral activity in CHB patients.

References

	Year	Citations

Page 1